Tiziana CEO buys 193,848 shares at $1.65 each

Tiziana Life Sciences LTD reported that its Chief Executive Officer, Ivor Elrifi, purchased 193,848 shares of Tiziana common stock in the open market.

Rhea-AI Filing Summary

Tiziana Life Sciences LTD reported that its Chief Executive Officer, Ivor Elrifi, purchased 193,848 shares of Tiziana common stock in the open market. The shares were bought at a price of $1.65 per share, indicating a direct increase in the CEO’s personal ownership stake. This transaction was disclosed in a Form 6-K, with additional details provided in a press release attached as an exhibit.

Insights

Equity Markets & Governance Analyst

CEO open-market share purchase signals increased personal exposure to Tiziana’s equity.

The filing states that Tiziana Life Sciences’ CEO, Ivor Elrifi, bought 193,848 shares of the company’s common stock in the open market at $1.65 per share. An open-market purchase means the CEO used personal funds to acquire shares at prevailing market prices, rather than receiving them as part of a compensation grant.

Such purchases often align the CEO’s financial interests more closely with other shareholders, because both now participate directly in the same share price outcomes. However, the filing does not quantify this purchase relative to total shares outstanding, so its overall scale cannot be assessed from this excerpt alone. The transaction details are further described in the attached press release dated September 9, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Tiziana Life Sciences (TLSA) disclose in this 6-K?

The company disclosed that its Chief Executive Officer, Ivor Elrifi, purchased 193,848 shares of Tiziana common stock in the open market at $1.65 per share.

Was the Tiziana Life Sciences (TLSA) CEO share purchase an open-market transaction?

Yes. The report states that CEO Ivor Elrifi bought 193,848 shares of Tiziana common stock in the open market at a price of $1.65 per share.

When did Tiziana Life Sciences (TLSA) announce the CEO’s share purchase?

Tiziana Life Sciences announced the CEO’s share purchase in a report dated September 9, 2025, with a related press release furnished as Exhibit 99.1.

Where can investors find more details on the Tiziana (TLSA) CEO share purchase?

Further details are included in the company’s press release titled Tiziana Life Sciences LTD Press Release, dated September 9, 2025, which is furnished as Exhibit 99.1 to the report.

Does the Tiziana Life Sciences (TLSA) 6-K state whether the CEO share purchase is being filed or furnished?

The report explains that the information in Exhibit 99.1 is being furnished and is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/09/2025 - 08:30 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

September 2025

Commission File Number:  001-38723

Tiziana Life Sciences LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On September 9, 2025, Tiziana Life Sciences LTD (the “Company”) issued this 6K announcing that its Chief Executive Officer, Ivor Elrifi, has purchased 193,848 shares of Tiziana common stock at a price of $1.65 per share in the open market.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TIZIANA LIFE SCIENCES LTD
Date: September 9, 2025	By:	/s/ Keeren Shah
		Name:	Keeren Shah
		Title:	Chief Financial Officer

2

EXHIBIT INDEX

Exhibit No.		Description
99.1		Tiziana Life Sciences LTD Press Release, dated September 9, 2025

3